Figure 3.
Response to EGFR-TKI therapy for the 6 patients with measurable disease. (A) Both patients receiving neoadjuvant TKI had a volumetric response (24), while 3 of 4 patients with advanced disease had a RECIST partial response. (B) CT imaging from one patient with advanced disease whose tumor demonstrated a marked response to erlotinib.